Cargando…

Galectin-3 and cyclin D1 expression in non-small cell lung cancer

INTRODUCTION: Lung cancer is a major cause of mortality and morbidity worldwide. Galectin-3 is multifunctional protein, which is involved in regulation of cell growth, cell adhesion, cell proliferation, angiogenesis and apoptosis. Cyclin D1 together with other cyclin plays an important role in cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosacka, Monika, Piesiak, Paweł, Kowal, Aneta, Gołecki, Marcin, Jankowska, Renata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3214148/
https://www.ncbi.nlm.nih.gov/pubmed/22024187
http://dx.doi.org/10.1186/1756-9966-30-101
_version_ 1782216209626824704
author Kosacka, Monika
Piesiak, Paweł
Kowal, Aneta
Gołecki, Marcin
Jankowska, Renata
author_facet Kosacka, Monika
Piesiak, Paweł
Kowal, Aneta
Gołecki, Marcin
Jankowska, Renata
author_sort Kosacka, Monika
collection PubMed
description INTRODUCTION: Lung cancer is a major cause of mortality and morbidity worldwide. Galectin-3 is multifunctional protein, which is involved in regulation of cell growth, cell adhesion, cell proliferation, angiogenesis and apoptosis. Cyclin D1 together with other cyclin plays an important role in cell cycle control. Cyclin D1 regulates the G1-to-S phase transition. The aim of this study was the evaluation of correlations between clinicopathological findings and cyclin D1 and galectin-3 expression in non-small cell lung cancer (NSCLC). We wanted also to analyze the prognostic value of cyclin D1 and galectin-3 expression. Moreover we tried to evaluate the correlations between galectin-3 and cyclin D1 expression in tumor tissue. MATERIALS AND METHODS: We used the immunochemistry method to investigate the expression of galectin-3 and cyclin D1 in the paraffin-embedded tumor tissue of 47 patients (32 men and 15 women; mean age 59.34 ± 8.90). years. We used monoclonal antibodies to cyclin D1 (NCL-L-cyclin D1-GM clone P2D11F11 NOVO CASTRA) and to galectin-3 (mouse monoclonal antibody NCL-GAL3 NOVO CASTRA). RESULTS: Galectin-3 expression was positive in 18 cases (38.29%) and cyclin D1 in 39 (82.97%). We showed only weak trend, that galectin-3 expression was lower in patients without lymph node involvement (p = 0.07) and cyclin D1 expression was higher in this group (p = 0.080). We didn't reveal differences in cyclin D1 and galectin-3 expression in SCC and adenocarcinoma patients. We didn't demonstrated also differences in galectin-3 and cyclin D1 expression depending on disease stage. Moreover we analyzed the prognostic value of cyclin D1 expression and galectin-3 in all examinated patients and separately in SCC and in adenocarcinoma and in all stages, but we didn't find any statistical differences. We demonstrated that in galectin-3 positive tumors cyclin D1 expression was higher (96.55% vs 61.11%, Chi(2 )Yatesa 7.53, p = 0.0061) and we revealed negative correlation between cyclin D1 and galectin-3 expression (R Spearman -0.458, p = 0.0011). In squamous cell lung cancer we didn't observed correlations between these both examinated markers (R = -0.158, p = 0.460), and in adenocarcinoma the negative correlation was very strong (R = -0.829 p = 0.000132). CONCLUSIONS: We didn't reveal any important correlations between clinicopathological findings and galectin-3 and cyclin D1 expression and in non small cell lung cancer. We didn't observed also prognostic value of cyclin D1 or galectin-3 expression. But we showed higher cyclin D1 expression in galectin-3 negative tumor tissues. We revealed also differences in correlations between galectin-3 and cyclin D1 expression in two main histopathological types of NSCLC.
format Online
Article
Text
id pubmed-3214148
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32141482011-11-12 Galectin-3 and cyclin D1 expression in non-small cell lung cancer Kosacka, Monika Piesiak, Paweł Kowal, Aneta Gołecki, Marcin Jankowska, Renata J Exp Clin Cancer Res Research INTRODUCTION: Lung cancer is a major cause of mortality and morbidity worldwide. Galectin-3 is multifunctional protein, which is involved in regulation of cell growth, cell adhesion, cell proliferation, angiogenesis and apoptosis. Cyclin D1 together with other cyclin plays an important role in cell cycle control. Cyclin D1 regulates the G1-to-S phase transition. The aim of this study was the evaluation of correlations between clinicopathological findings and cyclin D1 and galectin-3 expression in non-small cell lung cancer (NSCLC). We wanted also to analyze the prognostic value of cyclin D1 and galectin-3 expression. Moreover we tried to evaluate the correlations between galectin-3 and cyclin D1 expression in tumor tissue. MATERIALS AND METHODS: We used the immunochemistry method to investigate the expression of galectin-3 and cyclin D1 in the paraffin-embedded tumor tissue of 47 patients (32 men and 15 women; mean age 59.34 ± 8.90). years. We used monoclonal antibodies to cyclin D1 (NCL-L-cyclin D1-GM clone P2D11F11 NOVO CASTRA) and to galectin-3 (mouse monoclonal antibody NCL-GAL3 NOVO CASTRA). RESULTS: Galectin-3 expression was positive in 18 cases (38.29%) and cyclin D1 in 39 (82.97%). We showed only weak trend, that galectin-3 expression was lower in patients without lymph node involvement (p = 0.07) and cyclin D1 expression was higher in this group (p = 0.080). We didn't reveal differences in cyclin D1 and galectin-3 expression in SCC and adenocarcinoma patients. We didn't demonstrated also differences in galectin-3 and cyclin D1 expression depending on disease stage. Moreover we analyzed the prognostic value of cyclin D1 expression and galectin-3 in all examinated patients and separately in SCC and in adenocarcinoma and in all stages, but we didn't find any statistical differences. We demonstrated that in galectin-3 positive tumors cyclin D1 expression was higher (96.55% vs 61.11%, Chi(2 )Yatesa 7.53, p = 0.0061) and we revealed negative correlation between cyclin D1 and galectin-3 expression (R Spearman -0.458, p = 0.0011). In squamous cell lung cancer we didn't observed correlations between these both examinated markers (R = -0.158, p = 0.460), and in adenocarcinoma the negative correlation was very strong (R = -0.829 p = 0.000132). CONCLUSIONS: We didn't reveal any important correlations between clinicopathological findings and galectin-3 and cyclin D1 expression and in non small cell lung cancer. We didn't observed also prognostic value of cyclin D1 or galectin-3 expression. But we showed higher cyclin D1 expression in galectin-3 negative tumor tissues. We revealed also differences in correlations between galectin-3 and cyclin D1 expression in two main histopathological types of NSCLC. BioMed Central 2011-10-24 /pmc/articles/PMC3214148/ /pubmed/22024187 http://dx.doi.org/10.1186/1756-9966-30-101 Text en Copyright ©2011 Kosacka et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Kosacka, Monika
Piesiak, Paweł
Kowal, Aneta
Gołecki, Marcin
Jankowska, Renata
Galectin-3 and cyclin D1 expression in non-small cell lung cancer
title Galectin-3 and cyclin D1 expression in non-small cell lung cancer
title_full Galectin-3 and cyclin D1 expression in non-small cell lung cancer
title_fullStr Galectin-3 and cyclin D1 expression in non-small cell lung cancer
title_full_unstemmed Galectin-3 and cyclin D1 expression in non-small cell lung cancer
title_short Galectin-3 and cyclin D1 expression in non-small cell lung cancer
title_sort galectin-3 and cyclin d1 expression in non-small cell lung cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3214148/
https://www.ncbi.nlm.nih.gov/pubmed/22024187
http://dx.doi.org/10.1186/1756-9966-30-101
work_keys_str_mv AT kosackamonika galectin3andcyclind1expressioninnonsmallcelllungcancer
AT piesiakpaweł galectin3andcyclind1expressioninnonsmallcelllungcancer
AT kowalaneta galectin3andcyclind1expressioninnonsmallcelllungcancer
AT gołeckimarcin galectin3andcyclind1expressioninnonsmallcelllungcancer
AT jankowskarenata galectin3andcyclind1expressioninnonsmallcelllungcancer